Evogene Dividends and Buybacks
Dividend criteria checks 0/6
Evogene does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-45.5%
Buyback Yield
| Total Shareholder Yield | -45.5% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Evogene unit files for EPA approval of bio-fungicide LAV.311 for fruit rots
Oct 12Evogene unit launches 2nd-gen medical cannabis products in Israel
Sep 21Lavie Bio appoints Guri Oron as CEO
Sep 14Evogene GAAP EPS of -$0.42 misses by $0.23, revenue of $0.55M beats by $0.33M
Aug 31Evogene regains compliance with Nasdaq's minimum bid price requirement
Aug 25Evogen stock rises after unit gets $10M investment from ICL under collaboration agreement
Aug 17Update On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
Mar 22Evogene: Computational Biology Technology Hub; Focus On Canonic (Medical Cannabis)
Mar 03Evogene's Canonic Begins Selling High THC Cannabis In Israeli Medical Market
Sep 14Evogene: Bullish With Canonic's Entry Into Israeli Medical Cannabis Markets
Jun 16Evogene EPS beats by $0.01, beats on revenue
May 26Evogene unit - Canonic inks cultivation deal for medical cannabis varieties
Dec 23AgPlenus reaches a 'Lead' Stage in its mode-of-action herbicide program
Dec 15Evogene: Q3 Update And Upcoming Catalysts
Nov 30Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if EVGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EVGN's dividend payments have been increasing.
Dividend Yield vs Market
| Evogene Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (EVGN) | n/a |
| Market Bottom 25% (US) | 1.5% |
| Market Top 25% (US) | 4.7% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (EVGN) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate EVGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EVGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate EVGN's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EVGN has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 02:38 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evogene Ltd. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Benjamin Haynor | Alliance Global Partners |
| Kristen Kluska | Cantor Fitzgerald & Co. |